The Novo-backed medical implant provider has filed to raise up to $97.8m in an initial public offering that comes after $103m in funding.

The MIT-affiliated Engine Fund has achieved a final close of more than $205m, above its initial target of $150m.

Institut Curie has supplied an undisclosed sum to its second immuno-oncology spinout, Honing Biosciences, which will focus on improved drug delivery mechanisms.

Duke University’s OLV managed a near-50% increase on 2017’s spinout tally in a year where its businesses generated $526m in capital.

Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.

Novartis and Astellas Venture Management both invested as the gene therapy developer announced its first external funding.

Ping An Global Voyager Fund, Clal Insurance, Phoenix Insurance, Caesarea Medical and Foxconn all backed the diagnostics technology developer.

The healthcare communication platform developer has closed a $40.5m round backed by several health insurers and care providers.

Silverback Therapeutics, which is developing drugs that will only act at the site of disease, has closed a $47.5m round backed by Celgene.

David Broecker has become PRF’s chief innovation and collaboration officer, bringing with him expertise from the biosciences and philanthropic funding agency IBRI.